These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31410753)

  • 1. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
    Dong Z; Liao B; Shen W; Sui C; Yang J
    Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
    Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T
    Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
    Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
    Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
    Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
    Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1.
    Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
    J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M
    Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
    Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis.
    Xie Q; Wang L; Zheng S
    Dis Markers; 2020; 2020():1817931. PubMed ID: 32724483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.
    Shi RY; Yang XR; Shen QJ; Yang LX; Xu Y; Qiu SJ; Sun YF; Zhang X; Wang Z; Zhu K; Qin WX; Tang ZY; Fan J; Zhou J
    Cancer; 2013 Mar; 119(5):993-1003. PubMed ID: 23132676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
    Jin J; Ryu HS; Lee KB; Jang JJ
    PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
    Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
    Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Homer1 as a potential prognostic marker for intrahepatic cholangiocarcinoma.
    Wu SY; Yu MX; Li XG; Xu SF; Shen J; Sun Z; Zhou X; Chen XZ; Tu JC
    Asian Pac J Cancer Prev; 2014; 15(7):3299-304. PubMed ID: 24815486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.
    Lozzi I; Arnold A; Barone M; Johnson JC; Sinn BV; Eschrich J; Gebert P; Wang R; Hu M; Feldbrügge L; Schirmeier A; Reutzel-Selke A; Malinka T; Krenzien F; Schöning W; Modest DP; Pratschke J; Sauer IM; Felsenstein M
    Oncoimmunology; 2024; 13(1):2406052. PubMed ID: 39359389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in extrahepatic cholangiocarcinoma.
    Walter D; Herrmann E; Schnitzbauer AA; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
    Histopathology; 2017 Sep; 71(3):383-392. PubMed ID: 28419539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.